Ontology highlight
ABSTRACT:
SUBMITTER: Goyal L
PROVIDER: S-EPMC6677584 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Goyal Lipika L Shi Lei L Liu Leah Y LY Fece de la Cruz Ferran F Lennerz Jochen K JK Raghavan Srivatsan S Leschiner Ignaty I Elagina Liudmila L Siravegna Giulia G Ng Raymond W S RWS Vu Phuong P Patra Krushna C KC Saha Supriya K SK Uppot Raul N RN Arellano Ron R Reyes Stephanie S Sagara Takeshi T Otsuki Sachie S Nadres Brandon B Shahzade Heather A HA Dey-Guha Ipsita I Fetter Isobel J IJ Baiev Islam I Van Seventer Emily E EE Murphy Janet E JE Ferrone Cristina R CR Tanabe Kenneth K KK Deshpande Vikram V Harding James J JJ Yaeger Rona R Kelley Robin K RK Bardelli Alberto A Iafrate A John AJ Hahn William C WC Benes Cyril H CH Ting David T DT Hirai Hiroshi H Getz Gad G Juric Dejan D Zhu Andrew X AX Corcoran Ryan B RB Bardeesy Nabeel N
Cancer discovery 20190520 8
ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating <i>FGFR2</i> gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary <i>FGFR2</i> kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with <i>FGFR</i>2 fusion- ...[more]